Activity

CONCLUSION The combined treatment of CHM balneotherapy and NB-UVB could significantly prolong the remission time in patients with psoriasis vulgaris. This article is protected by copyright. All rights reserved.Sunitinib, a muiti-targeted receptor tyrosine kinase inhibitor including vascular endothelial growth factor, has been widely used as a first-line treatment against metastatic renal cell carcinoma (mRCC). However, mRCC often acquires resistance to sunitinib, rendering it difficult to treat with this agent. Recently, Rapalink-1, a drug that links rapamycin and the mTOR kinase inhibitor MLN0128, has been developed with excellent therapeutic effects against breast cancer cells carrying mTOR resistance mutations. The aim of this study was to evaluate the in vitro and in vivo therapeutic efficacy of Rapalink-1 against RCCs compared to temsirolimus, commonly used as a small molecule inhibitor of mTOR as a derivative of rapamycin. click here In comparison with temsirolimus, Rapalink-1 showed significantly greater effects against proliferation, migration, invasion and colony formation in sunitinib-naive RCC cells. Inhibition was achieved through suppression of the phosphorylation of substrates in the mTOR signal pathway such as p70S6K, 4EBP1, and AKT. In addition, Rapalink-1 had greater tumor suppressive effects than temsirolimus against the sunitinib-resistant 786-o cell line (SU-R 786-o), which we had previously established, as well as 3 additional SU-R cell lines established here. RNA sequencing showed that Rapalink-1 suppressed not only the mTOR signaling pathway but also a part of the MAPK signaling pathway, the ErbB signaling pathway and ABC transporters that were associated with resistance to several drugs. Our study suggests the possibility of a new treatment option in the treatment of patients with RCC that is either sunitinib-sensitive or -resistant. This article is protected by copyright. All rights reserved.Although much is known about surgical risk, little evidence exists regarding how best to proactively address preoperative risk factors to improve surgical outcomes. Preoperative malnutrition is a widely prevalent and modifiable risk factor in patients undergoing surgery. Malnutrition prior to surgery portends significantly higher postoperative mortality, morbidity, length of stay, readmission rates, and hospital costs. Unfortunately, perioperative malnutrition is poorly screened for and remains largely unrecognized and undertreated-a true “silent epidemic” in surgical care. To better address this silent epidemic of surgical nutrition risk, here we describe the rationalization, development, and implementation of a multidisciplinary, registered dietitian-driven, preoperative nutrition optimization clinic program designed to improve perioperative outcomes and reduce cost. Implementation of this novel Perioperative Enhancement Team (POET) Nutrition Clinic required a collaboration among many disciplines, as well as an identified need for multidimensional scheduling template development, data tracking systems, dashboard development, and integration of electronic health records. A structured malnutrition risk score (Perioperative Nutrition Screen score) was developed and is being validated. A structured malnutrition pathway was developed and is under study. Finally, the POET Nutrition Clinic has established a novel role for a perioperative registered dietitian as the integral point person to deliver perioperative nutrition care. We hope this structured model of perioperative nutrition assessment and optimization will allow for wide implementation and generalizability in other centers worldwide to improve recognition and treatment of perioperative nutrition risk. © 2020 The Authors. Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals, Inc. on behalf of American Society for Parenteral and Enteral Nutrition.A novel peptide stapling method effected by a double thiol-ene reaction between two cysteine residues and a divinyl diester to access stapled peptides with enhanced cell permeability is reported. This diverse chemical tool kit provides facile access to stapled peptides with varying bridge lengths. Stapled Axin mimetics were synthesised using this stapling method resulting in improved α-helicity relative to the unstapled peptide. Cell penetrating stapled analogues of the SIGK peptide that targets the protein-protein interaction hotspot of Gβγ proteins were also synthesized that exhibited a moderate increase in α-helicity and were cell permeable. This chemoselective peptide stapling method is highly amenable as a facile method to easily modify synthetic α-helical peptides to target intracellular proteins. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.OBJECTIVE Determining if traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are risk factors for Parkinson’s disease (PD). This constitutes a research priority for the Veterans Administration (VA) with implications for screening policy and prevention. METHODS Population-based, matched case-control study among veterans using VA healthcare facilities from 10/1/1999 to 09/30/2013. We identified 176,871 PD cases and 707,484 randomly selected PD-free matched controls. Parkinson’s Disease, TBI and PTSD were ascertained by validated ICD-9 code-based algorithms. We examined the association between both risk factors and PD employing race-adjusted conditional logistic regression. RESULTS The overall study cohort prevalence for TBI mild , TBI non-mild , and PTSD was 0.65%, 0.69% and 5.5% respectively. Both TBI and PTSD were significantly associated with PD in single-risk factor race-adjusted analyses (conditional odds ratio (cOR) =2.99 (95% CI 2.69-3.32), 3.82 (95% CI 3.67-3.97), and 2.71 (95% CI 2.66-2.77) for TBI mild , TBI non-mild and PTSD, respectively). There was suggestive positive interaction observed with comorbid PTSD/TBI in dual-risk factor analyses, with significant 2.69-fold and 3.70-fold excess relative PD risk in veterans with TBI mild and TBI non-mild vs. those without TBI when PTSD was present vs. 2.17-fold and 2.80-fold excess risk when PTSD was absent. INTERPRETATION Our study was the first to demonstrate that both TBI and PTSD are independently associated with increased relative PD risk in a diverse nationwide cohort of military service veterans, and the first to suggest a potential modest synergistic excess risk in those with comorbid TBI/PTSD. Longitudinal research is needed to confirm these suggestive findings. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.